CF
MGX icon

Corebridge Financial’s Metagenomi Therapeutics MGX Stock Holding History

Corebridge Financial’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,403
Closed -$18.2K – 2896
2025
Q1 		$18.2K Sell
13,403
-199
-1% -$474 ﹤0.01% 2913
2024
Q4 		$49.1K Buy
13,602
+10,228
+303% +$24.7K ﹤0.01% 2832
2024
Q3 		$7.32K Sell
3,374
-21
-0.6% -$73 ﹤0.01% 3026
2024
Q2 		$13.9K Buy
+3,395
New +$23.3K ﹤0.01% 3014

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Corebridge Financial's MGX Position: Q2 2025 in Review

Corebridge Financial sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 13,403 shares — an estimated $18.2K sold.

Corebridge Financial first reported a position in MGX in Q2 2024 and held it in 4 quarters. The position peaked at $49.1K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Corebridge Financial reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 13,403 Metagenomi Therapeutics shares in Q2 2025, an estimated $18.2K.
  • Corebridge Financial first reported a position in Metagenomi Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Metagenomi Therapeutics position peaked at $49.1K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.